NCT00666939View on ClinicalTrials.gov

A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance

PHASE3CompletedINTERVENTIONAL
Enrollment

773

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

January 31, 2005

Conditions
Transient Insomnia
Interventions
DRUG

Gabapentin

Gabapentin 100 mg oral capsule 30 minutes prior to bedtime

DRUG

Gabapentin

Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

DRUG

Placebo

Matched placebo 30 minutes prior to bedtime

Trial Locations (10)

10025

Pfizer Investigational Site, New York

10594

Pfizer Investigational Site, Thornwood

15904

Pfizer Investigational Site, Johnstown

16635

Pfizer Investigational Site, Duncansville

27612

Pfizer Investigational Site, Raleigh

30328

Pfizer Investigational Site, Atlanta

30342

Pfizer Investigational Site, Atlanta

34471

Pfizer Investigational Site, Ocala

70001

Pfizer Investigational Site, Metairie

92108

Pfizer Investigational Site, San Diego

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00666939 - A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance | Biotech Hunter | Biotech Hunter